Acasti Pharma, Inc (ACST)

[crudeoil24]

Uddin says no other drug or drug candidate has “come close to achieving these results” and that the results elevate the omega-3 drug class — including Acasti’s CaPre drug — to “blockbuster status” in the treatment of adverse cardiovascular events.

“Acasti’s CaPre is potentially a best-in-class OMG3 drug,” says Uddin. “We are significantly increasing our US sales estimates for CaPre – we believe CaPre has blockbuster potential. As an example, Lipitor achieved stronger sales than earlier-launched statins based on superior efficacy with no CV outcome data. CaPre should also become more attractive to potential licensees with the REDUCE-IT data.”

Uddin notes that currently available omega-3 drugs for severe hypertriglyceridemia have unwanted side effects, while CaPre has demonstrated in previous clinical studies to significantly lower triglycerides without elevating LCL cholesterol or having food effects, along with having an excellent safety profile and no fishy aftertaste.